Literature DB >> 21109324

Gender, renal function, and outcomes on the liver transplant waiting list: assessment of revised MELD including estimated glomerular filtration rate.

Robert P Myers1, Abdel Aziz M Shaheen, Alexander I Aspinall, Robert R Quinn, Kelly W Burak.   

Abstract

BACKGROUND & AIMS: The Model for End-Stage Liver Disease (MELD) allocation system for liver transplantation (LT) may present a disadvantage for women by including serum creatinine, which is typically lower in females. Our objectives were to investigate gender disparities in outcomes among LT candidates and to assess a revised MELD, including estimated glomerular filtration rate (eGFR), for predicting waiting list mortality.
METHODS: Adults registered for LT between 2002 and 2007 were identified using the UNOS database. We compared components of MELD, MDRD-derived eGFR, and the 3-month probability of LT and death between genders. Discrimination of MELD, MELDNa, and revised models including eGFR for mortality were compared using c-statistics.
RESULTS: A total of 40,393 patients (36% female) met the inclusion criteria; 9% died and 24% underwent LT within 3 months of listing. Compared with men, women had lower median serum creatinine (0.9 vs. 1.0 mg/dl), eGFR (72 vs. 83 ml/min/1.73 m(2)), and mean MELD (16.5 vs. 17.2; all p <0.0005), but within most MELD strata, had higher bilirubin and INR. After adjusting for relevant covariates including creatinine and body weight, women were less likely than men to receive a LT (hazard ratio [HR] 0.85; 95% CI 0.79-0.87) and had greater 3-month mortality (HR 1.13; 95% CI 1.05-1.21). Revision of MELD and MELDNa to include eGFR did not improve discrimination for 3-month mortality (c-statistics: MELD 0.896, MELD-eGFR 0.894, MELDNa 0.911, MELDNa-eGFR 0.905).
CONCLUSIONS: Women are disadvantaged under MELD potentially due to its inclusion of creatinine. However, since including eGFR in MELD does not improve mortality prediction, alternative refinements are necessary. Copyright Â
© 2010 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 21109324     DOI: 10.1016/j.jhep.2010.07.015

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  30 in total

1.  Center differences in model for end-stage liver disease exceptions: fairness, local culture, and norms of practice.

Authors:  Michael L Volk
Journal:  Liver Transpl       Date:  2013-10-10       Impact factor: 5.799

2.  Reduced Access to Liver Transplantation in Women: Role of Height, MELD Exception Scores, and Renal Function Underestimation.

Authors:  Alina M Allen; Julie K Heimbach; Joseph J Larson; Kristin C Mara; W Ray Kim; Patrick S Kamath; Terry M Therneau
Journal:  Transplantation       Date:  2018-10       Impact factor: 4.939

Review 3.  Gender-based disparities in access to and outcomes of liver transplantation.

Authors:  Omobonike O Oloruntoba; Cynthia A Moylan
Journal:  World J Hepatol       Date:  2015-03-27

Review 4.  Model for End-stage Liver Disease.

Authors:  Ashwani K Singal; Patrick S Kamath
Journal:  J Clin Exp Hepatol       Date:  2012-12-01

5.  Predicting in-hospital mortality among critically ill patients with end-stage liver disease.

Authors:  Alex A Balekian; Michael K Gould
Journal:  J Crit Care       Date:  2012-10-09       Impact factor: 3.425

Review 6.  Model for end-stage liver disease: end of the first decade.

Authors:  Sumeet K Asrani; W Ray Kim
Journal:  Clin Liver Dis       Date:  2011-10-01       Impact factor: 6.126

7.  Cystatin C Is a Gender-Neutral Glomerular Filtration Rate Biomarker in Patients with Cirrhosis.

Authors:  Ayse L Mindikoglu; Antone R Opekun; William E Mitch; Laurence S Magder; Robert H Christenson; Thomas C Dowling; Matthew R Weir; Stephen L Seliger; Charles D Howell; Jean-Pierre Raufman; Abbas Rana; John A Goss; Saira A Khaderi; John M Vierling
Journal:  Dig Dis Sci       Date:  2018-02-01       Impact factor: 3.199

8.  Comparative effectiveness of liver transplant strategies for end-stage liver disease patients on renal replacement therapy.

Authors:  Yaojen Chang; Lorenzo Gallon; Colleen Jay; Kirti Shetty; Bing Ho; Josh Levitsky; Talia Baker; Daniela Ladner; John Friedewald; Michael Abecassis; Gordon Hazen; Anton I Skaro
Journal:  Liver Transpl       Date:  2014-09       Impact factor: 5.799

9.  Impact of estimated liver volume and liver weight on gender disparity in liver transplantation.

Authors:  Ayse L Mindikoglu; Sukru H Emre; Laurence S Magder
Journal:  Liver Transpl       Date:  2012-12-12       Impact factor: 5.799

Review 10.  Care of the liver transplant patient.

Authors:  Mamatha Bhat; Said Al-Busafi; Marc Deschênes; Peter Ghali
Journal:  Can J Gastroenterol Hepatol       Date:  2014-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.